Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 16/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | PTPRC | P08575 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8700991 | 1.00 | TERT (1.00) | TERTMEN1NPC1ALDH1A1CYP1A2 | |
| SCHEMBL9630529 | 0.85 | TERT (1.00) | TERTMEN1NPC1ALDH1A1CYP1A2 | |
| SCHEMBL4303627 | 0.85 | TERT (1.00) | TERTMEN1NPC1ALDH1A1CYP1A2 | |
| SCHEMBL19012211 | 0.85 | TERT (0.74) | TERTMEN1NPC1ALDH1A1CYP1A2 | |
| SCHEMBL4291524 | 0.84 | TERT (0.73) | TERTMEN1NPC1ALDH1A1CYP1A2 | |
| SCHEMBL8700770 | 0.84 | TERT (0.82) | TERTMEN1NPC1ALDH1A1CYP1A2 | |
| SCHEMBL4298269 | 0.83 | PTPRC (0.83) | TERTMEN1NPC1ALDH1A1CYP1A2 | |
| SCHEMBL8705890 | 0.82 | TERT (0.75) | TERT | |
| SCHEMBL8701507 | 0.82 | TERT (0.78) | TERTMEN1NPC1ALDH1A1CYP1A2 | |
| SCHEMBL8701369 | 0.81 | TERT (0.85) | TERTMEN1NPC1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2009-10-08 | — | — | US | disclosed |
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2009-10-08 | — | — | US | disclosed |
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2009-10-08 | — | — | US | disclosed |
| WO-1998025884-A1 | FURTHER ANTHRAQUINONES WITH BIOLOGICAL ACTIVITY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | TERT, NAT10, POT1 | TERT 1/4885MEN1 148/4885NPC1 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.